β-catenin activated hepatocellular adenoma

Chu, Hyun Hee; Moon, Woo Sung

doi:10.3350/cmh.2013.19.2.185

Cited by 6 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the four HCA subtypes, (exon 3) b-HCAs are known to trigger a potent mitogenic signaling pathway that is prominent in HCC [ Zucman-Rossi et al 2007 ; Chu and Moon, 2013 ; Pilati et al 2014 ], which suggests a positive correlate between the two. Zucman-Rossi and colleagues reported an incidence of HCCs, or borderline malignant tumors in b-HCAs, of up to 46%; this malignant progression was seldom seen in other subtypes [ Zucman-Rossi et al 2007 ], and was over-represented for male patents (5 cases, 38%; p = 0 .02) [ Hussain et al 2006 ].…”

Section: Reviewing the Known Complicationsmentioning

confidence: 99%

Hepatocellular adenoma: when and how to treat? Update of current evidence

Thomeer

Bröker

Verheij

et al. 2016

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Hepatocellular adenoma (HCA) is a rare, benign liver tumor. Discovery of this tumor is usually as an incidental finding, correlated with the use of oral contraceptives, or pregnancy. Treatment options have focused on conservative management for the straightforward, smaller lesions (<5 cm), with resection preferred for larger lesions (>5 cm) that pose a greater risk of hemorrhage or malignant progression. In recent years, a new molecular subclassification of HCA has been proposed, associated with characteristic morphological features and loss or increased expression of immunohistochemical markers. This subclassification could possibly provide considerable benefits in terms of patient stratification, and the selection of treatment options. In this review we discuss the decision-making processes and associated risk analyses that should be made based on lesion size, and subtype. The usefulness of this subclassification system in terms of the procedures instigated as part of the diagnostic work-up of a suspected HCA will be outlined, and suitable treatment schemes proposed.

show abstract

Section: Reviewing the Known Complicationsmentioning

confidence: 99%

Hepatocellular adenoma: when and how to treat? Update of current evidence

Thomeer

Bröker

Verheij

et al. 2016

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Intracellular lipids were not present in any of the β-catenin activated HCA cases [ 2 ]. However, a β-catenin activated HCA case containing focal fatty areas and showing malign transformation was reported later [ 2 5 6 ].…”

Section: Discussionmentioning

confidence: 99%

“…In literature, diffuse steatosis, which is defined as the feature of HNF-1α-inactivated HCA subtype, has not been previously reported in any β-catenin activated HCA case [ 2 ]. To the best of our knowledge, only a few case ware described in literature containing internal fat deposits [ 4 5 6 ].…”

Section: Introductionmentioning

confidence: 99%

Atypical β-Catenin Activated Child Hepatocellular Tumor

Turan

Ünlü

Karakuş

et al. 2015

Pediatr Gastroenterol Hepatol Nutr

View full text Add to dashboard Cite

Hepatocellular adenomas are a benign, focal, hepatic neoplasm that have been divided into four subtypes according to the genetic and pathological features. The β-catenin activated subtype accounts for 10-15% of all hepatocellular adenomas and specific magnetic resonance imaging features have been defined for different hepatocellular adenomas subtypes. The current study aimed to report the magnetic resonance imaging features of a well differentiated hepatocellular carcinoma that developed on the basis of β-catenin activated hepatocellular adenomas in a child. In this case, atypical diffuse steatosis was determined in the lesion. In the literature, diffuse steatosis, which is defined as a feature of the hepatocyte nuclear factor-1α-inactivated hepatocellular adenomas subtype, has not been previously reported in any β-catenin activated hepatocellular adenomas case. Interlacing magnetic resonance imaging findings between subtypes show that there are still many mysteries about this topic and larger studies are warranted.

show abstract

“…HCA represents a heterogeneous group of tumors that differ in histology, immunophenotype, molecular pathogenesis, and biological behavior. Based on these factors, HCAs can be sub-classified into the following four major groups: HNF1α-inactivated HCA, β-catenin activated HCA, inflammatory HCA, and unclassified HCA [ 2 - 5 ]. Approximately 10% of inflammatory HCA cases coexist with a β-catenin mutation [ 2 , 4 ].…”

mentioning

confidence: 99%

Hepatocellular Carcinoma Arising in a Huge Hepatocellular Adenoma with Bone Marrow Metaplasia

Kang

Jeong

Kim

et al. 2018

J Pathol Transl Med

View full text Add to dashboard Cite

Hepatocellular adenoma (HCA) is the most common type of benign liver tumor, and its major complication is malignant transformation to hepatocellular carcinoma (HCC). Here, we report a case of HCC arising in HCA with bone marrow metaplasia in a 24-year-old Korean woman who presented with abdominal discomfort. A huge liver mass was found on abdominal ultrasonography. She underwent surgical hepatic resection, and the resected specimen was entirely involved by a 20-cm-sized tumor. Histological review revealed a well differentiated HCC arising from inflammatory HCA with β-catenin nuclear positivity and bone marrow metaplasia that contained hematopoietic cells. This case was unique because malignant transformation, inflammatory type HCA, β-catenin nuclear staining, and bone marrow metaplasia were simultaneously observed. Additionally, it should be noted that a large HCA with β-catenin activation can undergo malignant transformation and should be surgically resected in a timely manner.

show abstract

β-catenin activated hepatocellular adenoma

Cited by 6 publications

References 11 publications

Hepatocellular adenoma: when and how to treat? Update of current evidence

Hepatocellular adenoma: when and how to treat? Update of current evidence

Atypical β-Catenin Activated Child Hepatocellular Tumor

Hepatocellular Carcinoma Arising in a Huge Hepatocellular Adenoma with Bone Marrow Metaplasia

Contact Info

Product

Resources

About